Xolair (omalizumab) - Roche, Novartis
AK002 - Allakos
https://www.annallergy.org/article/S1081-1206(19)30845-2/fulltext
 
S. Altrichter; P. Staubach; M. Pasha; H. Rasmussen; B. Singh; A. Chang; A. Kamboj; J. Bernstein; F. Siebenhaar; M. Maurer
 
Nov 9, 2019
 
Prev Next